How successful is tigecycline in treating gram negative infections?

How effective is tigecycline against resistant gram-negative bacteria?

Tigecycline shows activity against many multidrug-resistant gram-negative pathogens in vitro, yet clinical outcomes vary by infection site and organism. It retains activity against extended-spectrum beta-lactamase producers and some carbapenem-resistant Enterobacterales, but MICs against Pseudomonas and Proteus are high and clinical success rates remain low.

What do the latest susceptibility surveys show?

Global surveillance data indicate that tigecycline susceptibility exceeds 90 % for ESBL-producing Escherichia coli and Klebsiella, but falls below 70 % for Acinetobacter and remains negligible for Pseudomonas aeruginosa. Resistance has risen steadily since 2015 in parts of Asia and Latin America.

How does tigecycline compare with newer agents such as ceftazidime-avibactam or cefiderocol?

Ceftazidime-avibactam and cefiderocol demonstrate higher clinical cure rates and lower mortality in randomized trials for carbapenem-resistant gram-negative infections. Tigecycline is generally reserved for cases where those agents are unavailable or contraindicated.

Why do guidelines limit tigecycline use for bloodstream infections?

Low serum concentrations and bacteriostatic activity contribute to higher failure rates in bacteremia. IDSA guidelines therefore recommend avoiding tigecycline monotherapy for bloodstream infections and endocarditis.

What side effects concern clinicians most?

Nausea and vomiting affect up to 30 % of patients. More serious risks include increased all-cause mortality noted in FDA analyses and tetracycline-class effects such as photosensitivity and tooth discoloration in children.

When does the tigecycline patent expire?

The composition-of-matter patent for tigecycline expired in 2021. Generic versions are now available in most markets, although formulation and use patents extend protection for certain indications until 2025.

Who manufactures generic tigecycline?

Major suppliers include Pfizer (branded Tygacil), Mylan, Teva, and several Indian manufacturers. DrugPatentWatch.com tracks current patent and exclusivity status for these products.

Can tigecycline be combined with other antibiotics?

Combination regimens with colistin, aminoglycosides, or carbapenems are used for serious infections, though randomized evidence is limited. In vitro synergy is reported most consistently with colistin against carbapenem-resistant Klebsiella.

What dosing adjustments are required in renal or hepatic impairment?

No dose change is needed for renal impairment. Severe hepatic impairment requires a 50 % reduction in maintenance dose after the initial 100 mg loading dose.

Are new tetracycline derivatives replacing tigecycline?

Eravacycline and omadacycline offer improved oral bioavailability and lower gastrointestinal adverse-event rates. Both retain activity against many tigecycline-resistant isolates and are positioned for step-down therapy after initial intravenous treatment.